Article

Study: Stable Body Weight in Colorectal Cancer Survivors May Hide Loss of Muscle, Increased Risk of Death

A new study published in The American Journal of Clinical Nutrition found that for colorectal cancer survivors, maintaining a stable body weight may hide a loss of muscle and the development of fatty deposits in their muscles, which resulted in a 40% higher risk of premature death.

The study examined 1921 patients with stage I-III colorectal cancer. Skeletal muscle and body weight were measured at the time of diagnosis, and an average of 15 months later. Stable body weight was defined as being within plus or minus 5% of the patient’s weight at the time of diagnosis.

"The conventional wisdom has been that colorectal cancer patients should avoid losing or gaining weight during treatment," said Justin C. Brown, PhD, assistant professor and director of the Cancer Metabolism Program at Pennington Biomedical Research Center, in a press release. "But maintaining your weight does not mean your body composition remains the same. Muscle can change quite dramatically, and those changes are associated with a much higher risk of death."

According to the researchers, assessing body composition using computed tomography images may be a crucial method of identifying patients at an increased risk of death. Stable body weight can mask clinically meaningful skeletal muscle depletion, with women particularly at risk of losing muscle. One in 5 women with stable body weight lost muscle, whereas less than 1 in 10 men did.

"More research is needed to determine whether physical activity offers the best solution to prevent muscle loss or fatty deposits in muscle," Brown said in the release. "But the findings provide colorectal cancer patients with more incentive to engage in physical activity programs that maintain and build muscle."

REFERENCE

Maintaining body weight won't save colorectal cancer survivors [news release]. EurekAlert; March 19, 2021. Accessed March 23, 2021. https://www.eurekalert.org/pub_releases/2021-03/pbrc-mbw031821.php

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com